PXL 770
Alternative Names: PXL-770Latest Information Update: 19 Feb 2024
At a glance
- Originator Poxel
- Class Antihyperglycaemics; Cardiovascular therapies; Hepatoprotectants; Heterocyclic compounds; Naphthalenes; Potassium compounds; Pyridines; Small molecules; Urologics
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adrenoleucodystrophy; Non-alcoholic fatty liver disease
- Phase I Autosomal dominant polycystic kidney disease
- Preclinical Cardiomyopathies
- No development reported Non-alcoholic steatohepatitis
- Discontinued Type 2 diabetes mellitus